Longeveron closes $5.0M public offering (up to $17.5M with warrants) for laromestrocel development

Longeveron Inc.

Gross proceeds $5.0M upfront from offering of ~5.88M shares/pre-funded warrants and 14.7M short-term warrants at $0.85 combined price.
Potential additional $12.5M if short-term warrants (exercisable at $0.85, 24-month term) are fully cash-exercised.
Proceeds to fund clinical/regulatory development of laromestrocel for HLHS, Alzheimer's, pediatric DCM, and BLA readiness.
Placement agent H.C. Wainwright received 7% cash fee plus warrants at $1.0625; board members and insiders participated.
Company subject to 60-day equity issuance lock-up and one-year variable rate transaction ban.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.